上海海顺新型药用包装材料股份有限公司 第五届董事会独立董事专门会议2025年第二次会议决议 一、独立董事专门会议召开情况 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届董事会独立董事专门会议 2025 年第二次会议（以下简称"独 立董事专门会议"）于 2025 年 4 月 15 日以现场会议的方式召开，本 次会议应出席独立董事 3 人，实际出席独立董事 3 人，符合《公司章 程》和《上市公司独立董事管理办法》的有关规定。本次会议通知提 前以电子邮件及电话通知等方式向全体独立董事送达。公司独立董事 郭珣先生召集和主持了本次会议。 本次独立董事专门会议的召开符合中国证监会《上市公司独立董 事管理办法》及《公司章程》《独立董事工作制度》的有关规定。 二、独立董事专门会议审议情况 经与会独立董事认真审议，通过了以下议案： （一）审议通过《关于公司2024年度利润分配预案的议案》 2024 年度利润分配预案充分考虑了公司实际经营、资金情况以 及未来发展需要，未违反《公司法》及《公司章程》的相关规定，未 损害公司股东尤其是中小股东的利益。因此，独立董事一致同意公司 2024 年度利润分配预案并同意提交公 ...

| 证券代码：300501 | 证券简称：海顺新材 公告编号：2025-032 | | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | 上海海顺新型药用包装材料股份有限公司 关于2024年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2025年4月16日召开了第五届董事会第三十六次会议和第五届监事 会第二十四次会议，审议通过了《关于公司2024年度利润分配预案的 议案》，该议案尚需提交股东大会审议。 （一）董事会审议情况 公司第五届董事会第三十六次会议审议通过了《关于公司2024年 度利润分配预案的议案》，董事会认为，公司2024年度利润分配预案 符合公司发展需要，符合《公司章程》等相关制度规定，具备合法性、 合规性、合理性。同意将该议案提请股东大会审议。 表决结果：同意7票、反对0票、弃权0票。 （二）监事会审议情况 公司第五届监事会第二十四次会议审议通过了《关于公司2024年 度利润分配预案的议案》。监事会经审议后认为：公司《关 ...

Dividend Distribution - The company plans to distribute a cash dividend of 2.7 CNY per 10 shares (including tax) to all shareholders, with no bonus shares issued[3]. - The company plans to distribute a cash dividend of RMB 2.7 per 10 shares (including tax) for the first three quarters of 2024, with a total dividend amounting to RMB 50,850,235.62 (including tax) based on a total share capital of 193,537,806 shares as of September 30, 2024[165]. - The actual cash dividend distributed for the fiscal year 2023 was RMB 28,660,530.90 (including tax), calculated from a total share capital of 193,531,895 shares after accounting for repurchased shares[164]. - The company has not issued any bonus shares or capital reserves for the current fiscal year, and the remaining undistributed profits will be carried forward to the next fiscal year[167]. Financial Performance - The company's operating revenue for 2024 was ¥1,142,549,822.03, representing an increase of 11.92% compared to ¥1,020,872,006.74 in 2023[17]. - The net profit attributable to shareholders for 2024 decreased by 12.70% to ¥74,589,975.03 from ¥85,441,741.28 in 2023[17]. - The cash flow from operating activities increased significantly by 60.35% to ¥161,307,846.86 in 2024, compared to ¥100,596,592.11 in 2023[17]. - The basic earnings per share for 2024 was ¥0.39, down 11.36% from ¥0.44 in 2023[17]. - The total assets at the end of 2024 were ¥2,885,699,417.44, a decrease of 3.38% from ¥2,986,593,236.85 at the end of 2023[17]. - The company reported a net profit of ¥4,974,701.38 from non-recurring gains and losses in 2024, down from ¥16,997,149.67 in 2023[23]. - In 2024, the company achieved a revenue of 1.143 billion yuan, representing a year-on-year growth of 11.92%[43]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 69.6153 million yuan, an increase of 1.71% year-on-year[43]. Market and Industry Trends - The global pharmaceutical packaging market is projected to grow from $134.18 billion in 2024 to $180 billion by 2029, with a CAGR of approximately 6.2%[26]. - The domestic pharmaceutical packaging materials sub-industry is expected to see a revenue growth rate of 3% in 2024, driven by stable market demand and policy support[26]. - The pharmaceutical packaging industry is experiencing increased concentration due to high technical and capital requirements, leading to the elimination or acquisition of smaller companies unable to adapt to industry trends[28]. - The demand for pharmaceutical packaging materials is directly linked to drug consumption, exhibiting weak cyclical characteristics as pharmaceuticals are essential consumer goods[28]. Research and Development - The company reported a significant focus on research and development of new drug packaging materials to enhance market competitiveness[3]. - The company's R&D investment reached 52.32 million yuan in 2024, marking a 3.91% increase compared to the previous year[43]. - The company is focusing on developing recyclable and biodegradable materials to contribute to the industry's green development[27]. - The company is developing a new anti-counterfeiting cold-pressed aluminum composite sheet, currently in the small batch trial production phase[61]. - The company is also working on a high-barrier liquid packaging film and its packaging bags, aimed at extending the shelf life of liquid medicines[61]. - The company is developing a lightweight cold-pressed aluminum composite sheet with a thickness of 140-160um, aiming to improve barrier performance while reducing weight[62]. Operational Efficiency - The company has established a robust financial reporting framework to ensure transparency and accuracy in its financial disclosures[3]. - The company utilizes an ERP system for production management, ensuring efficiency and quality control throughout the manufacturing process[37]. - The company has developed a digital management system across the entire supply chain to enhance operational efficiency and reduce production costs[42]. - The company has implemented a talent incentive mechanism to retain key personnel, ensuring that their expertise and experience contribute to the company's competitive edge[121]. Compliance and Governance - The company emphasizes the importance of maintaining compliance with Good Manufacturing Practices (GMP) to ensure product quality and safety[11]. - The company has established a comprehensive quality management system, achieving multiple certifications including ISO13485 and FSSC22000[46]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, and operations[135]. - The company has engaged professional lawyers to ensure compliance during shareholder meetings[130]. - The company’s governance practices align with the regulations set forth by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[134]. Environmental Responsibility - The company complies with various environmental protection laws and standards, including the Air Pollution Prevention and Control Law and the Water Pollution Prevention and Control Law[179]. - The company is listed as a key regulatory unit for environmental risk control by the Zhejiang Provincial Ecological Environment Department and the Suzhou Ecological Environment Bureau[178]. - The company has obtained pollution discharge permits for its subsidiaries, with validity periods extending to 2029[180]. - The company conducts internal inspections and external testing to ensure compliance with pollution discharge standards[181]. Strategic Investments - The company plans to invest 4,675 million RMB in Zhejiang Duoling Pharmaceutical Packaging Materials Co., increasing its stake to 68% and enhancing production capacity to 1,500 tons of high-barrier pharmaceutical packaging composite film annually[106]. - The company has made a strategic investment of 21,507.5 million RMB to acquire a 43.015% stake in Shanghai Jiucheng Packaging Co., enhancing its presence in the fast-moving consumer goods packaging sector[107]. - The company is focusing on expanding its market presence through strategic investments and partnerships[78]. Employee Engagement and Development - The total number of employees at the end of the reporting period is 1,018, with 645 in production, 119 in sales, 136 in technology, 29 in finance, and 89 in administration[160][161]. - The company emphasizes employee training and development, planning to enhance its high-level talent training system by 2025 to improve employee professional skills and service levels[163]. - The company has established a competitive salary management system, with performance-based salary adjustments and annual performance bonuses linked to individual and company performance[162]. Risk Management - The company faces various risks including market competition, raw material price fluctuations, and potential declines in gross margin[3]. - The company faces risks from raw material price fluctuations, with significant cost contributions from aluminum foil and plastic particles, which are influenced by macroeconomic conditions and supply-demand dynamics[118]. - To mitigate raw material price risks, the company has established long-term relationships with multiple suppliers and employs a cost transmission mechanism to adjust product pricing accordingly[118]. - The company is addressing capacity digestion risks by closely monitoring market dynamics and optimizing production processes to maintain high capacity utilization rates[119].

中信证券股份有限公司 关于上海海顺新型药用包装材料股份有限公司 2024 年度募集资金存放与使用情况的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为上海海 顺新型药用包装材料股份有限公司（以下简称"海顺新材"、"上市公司"或"公 司"）向特定对象发行股票与向不特定对象发行可转换公司债券的保荐人，根据 《证券发行上市保荐业务管理办法》等有关规定，对海顺新材 2024 年度募集资 金存放与使用情况进行了核查，核查情况如下： 一、募集资金基本情况 （一）2021 年向特定对象发行股票 1、实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意上海海顺新型药用包装材料股份有 限公司向特定对象发行股票注册的批复》（证监许可〔2021〕2377 号），公司 由主承销商中信证券股份有限公司采用询价方式，向特定对象发行人民币普通股 （A 股）股票 37,181,705 股，发行价为每股人民币 16.18 元，共计募集资金 601,599,986.90 元，坐扣承销和保荐费用 3,309,433.90 元（不含税）以及税金 198,566.03 元后的募集资金为 598,091,986.9 ...

目 录 | 一、审计报告……………………………………………………… 第 1—5 | | 页 | | --- | --- | --- | | 二、财务报表……………………………………………………… 第 6—13 | | 页 | | （一）合并资产负债表…………………………………………… | 第 | 6 页 | | （二）母公司资产负债表………………………………………… | 第 | 7 页 | | （三）合并利润表………………………………………………… | 第 | 8 页 | | （四）母公司利润表……………………………………………… | 第 | 9 页 | | （五）合并现金流量表……………………………………………第 | | 10 页 | | （六）母公司现金流量表…………………………………………第 | | 11 页 | | （七）合并所有者权益变动表……………………………………第 | | 12 页 | | （八）母公司所有者权益变动表…………………………………第 | | 13 页 | | | | 审 计 报 告 天健审〔2025〕2-234 号 上海海顺新型药用包装材料股份有限公司全体股东： 一、审计意见 我 ...

中信证券股份有限公司 关于上海海顺新型药用包装材料股份有限公司向不特定对 象发行可转换公司债券部分募投项目调整建设投资规模、结 项并将节余募集资金永久补充流动资金的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为上海海顺 新型药用包装材料股份有限公司（以下简称"海顺新材"、"上市公司"或"公 司"）2023 年向不特定对象发行可转换公司债券的保荐机构，根据《证券发行 上市保荐业务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》等相关法律法规规定的要求，对公司向不特定对象发行可转 换公司债券部分募投项目调整建设投资规模、结项并将节余募集资金永久补充流 动资金事项进行了认真、审慎的核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意上海海顺新型药用包装材料股份有 限公司向不特定对象发行可转换公司债券注册的批复》(证监许可〔2023〕53 号)， 发行总额为人民币 633,000,000.00 元，扣除承销及保荐费 4,590,000.00 元（含 增值税）后的募集资金为 628,410,00 ...

海顺新材（300501）公告，2024年营业收入11.43亿元，同比增长11.92%。归属于上市公司股东的净利 润7459万元，同比下降12.70%。公司拟向全体股东每10股派发现金红利2.7元(含税)，送红股0股(含 税)，以资本公积金向全体股东每10股转增0股。 ...

上海海顺新型药用包装材料股份有限公司 2024年度独立董事述职报告 （王琳琳） 作为上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届董事会独立董事，2024年度，本人严格按照《中华人民共和国 公司法》《中华人民共和国证券法》《深圳证券交易所上市公司自律 监管指引第2号——创业板上市公司规范运作》《公司章程》以及《公 司独立董事工作制度》等有关法律、法规、制度的规定和要求，恪尽 职守，勤勉尽责，促进公司的规范运作，维护全体股东尤其是中小股 东的利益，充分发挥独立董事的作用。现将本人2024年度担任公司独 立董事的履职情况报告如下： 一、独立董事基本情况 本人王琳琳，中国国籍，无境外永久居留权，1967 年 2 月出生， 硕士研究生学历，高级会计师。曾任中远集装箱运输有限公司财务副 经理、招商局集团计财部财务管理室主任、招商局运输集团有限公司 财务总监、香港明华船务公司财务总监、招商局能源运输股份有限公 司副总经理兼财务总监、上海国际港务（集团）股份有限公司副财务 总监、副总裁等。现任上海实业发展股份有限公司独立董事、陆家嘴 金融贸易区开发股份有限公司独立董事、本公司独立董事。 报告期内，本人任职 ...

上海海顺新型药用包装材料股份有限公司 2024年度独立董事述职报告 （夏宽云-已离任） 作为上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届董事会独立董事，在任职期间，本人严格按照《中华人民共和 国公司法》《中华人民共和国证券法》《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》《公司章程》以及 《公司独立董事工作制度》等有关法律、法规、制度的规定和要求， 恪尽职守，勤勉尽责，促进公司的规范运作，维护全体股东尤其是中 小股东的利益，充分发挥独立董事的作用。 2024年6月，本人因在境内上市公司任职即将超过三家，经过慎 重考虑，申请辞去独立董事及其担任的董事会专门委员会职务，辞职 后，本人不再担任公司及子公司任何职务。 现将本人2024年度担任公司独立董事期间的履职情况报告如下： 一、独立董事基本情况 本人夏宽云，中国国籍，拥有希腊永久居留权，1962年3月出生， 博士研究生学历，高级会计师。历任宁波大学国际金融学院团总支书 记和会计系主任、上海贝岭股份有限公司财务部总监、上海国家会计 学院副教授、东方有线网络有限公司财务部总经理，浙江九洲药业股 份有限公司董事、财务总监， ...